Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
CC-95266-MM-001
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT04674813 ↗
- Completed
- Juno Therapeutics, a Subsidiary of Celgene
- Focused
We haven't built an HCP commentary report on CC-95266-MM-001 (CC-95266, fludarabine and 2 more in Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CC-95266-MM-001 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- CC-95266; Fludarabine; Cyclophosphamide; Bendamustine
- Arms
- Administration of CC-95266 · Experimental
- Enrollment
- 130
- Primary outcomes
- Number of participants with Adverse Events (AEs)
- Number of participants with significant laboratory abnormalities
- Number of participants with Dose Limiting Toxicities (DLTs)
- Maximum Tolerated Dose (MTD)
- Recommended Phase 2 Dose (RP2D)
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Start
- Feb 24, 2021
- Primary completion
- Dec 22, 2025
- Results posted
- No
- Registry record
- NCT04674813 · updated Feb 9, 2026
Publications
linked from the registry- Bal S, Htut M, Nadeem O, Anderson LD Jr, Gregory T, Kocoglu MH, Rossi AC, Martin T, Egan DN, Costa LJ, Hu H, Chen J, Li S, Kelly LM, Sarkis N, Ziyad S, Jordahl KM, Kao WM, Kaeding AJ, Burgess MR, Berdeja JG. Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma. Blood. 2026 Sep 3;148(10):1240-1250. doi: 10.1182/blood.2025030750. PubMed 42233419